Lyme Disease Diagnostic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Lyme Disease Diagnostic market is segmented by Diagnostic Technology (Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining, Nucleic Acid Test),End User (Hospitals, Clinical laboratories) and Geography.

Market Snapshot

Lyme Disease Diagnostic Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Lyme Disease Diagnostic Market is expected to register a CAGR of 5.5% during the forecast period. The Lyme disease diagnostic market is growing at a good rate owing to factors such as rise in prevalence of lyme disease and emergence of new lyme diagnostic tests. A Lyme disease is a caused by the bacterium borrelia burgdorferi and transmitted through a bite of infected blacklegged deer tick in humans. Several test such as ELISA test used to detect antibodies to B. burgdorferi. If the ELISA test is positive, then further Western blot test is carried out to detect proteins of B. burgdorferi. Moreover, increasing number of cases of tick born diseases is also promoting the growth of lyme disease diagnostic market. For instance, in 2018, according to Centers for Disease Control and Prevention number of cases of tick-borne diseases reported was 47,743, leading to adoption of lyme disease diagnostic tests. Furthermore, rising incidences of new vector borne diseases, growing givernment initiatives and rising healthcare expenditure are some more factors which are fueling the market growth.

Scope of the Report

As per the scope, Lyme disease diagnostic market is concentrating on the emerging diagnostic technologies, several types of diagnostic test such as serological, lymphocytic transformation test, Urine Antigen Testing, Immunofluorescent staining, Nucleic acid test. Lyme Disease Diagnostic Market is segmented by diagnostic technology, End User and Geography.

By diagnostic technology
Serological test
ELISA
Western Blot
Lymphocytic transformation test
Urine Antigen Testing
Immunofluorescent staining
Nucleic acid test
By End User
Hospitals
Clinical laboratories
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Serological​ test Segment is Expected to be a largest growing segment in the Lyme Disease Diagnostic Market.

Serological test is a diagnostic method that is particularly used for identifying antibodies and antigens in patients sample which can be serum, plasma, semen and saliva.

Serological test is expected to dominant the segment as this test is highly preferable among all the test owing to measures the antibodies in the late phase of the illness when both nucleic acid test and polymerase chain reaction test is negative. These tests are very beneficial in terms of evaluating Lyme disease. Serological tests includes ELISA, agglutination, precipitation and western blot methods used to identify infectious diseases. Moreover, rising prevalence lyme disease and growing demand of diagnostic tests among targeted patient pool opt for this test and promote the lyme disease diagnostic market.

segmentation.PNG

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

 North America is expected to hold a significant market share in the global lyme disease diagnostic market. This can be attributed to increasing prevalence of tick borne diseases, increasing initiatives by government and private institute for diagnosing the yme disease in this region. For instance, according to Centers for Disease Control and Prevention(CDC), around 300000 people were diagnosed with Lyme disease every year in North America. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fuelling the growth of the overall regional market to a large extent.

321.png

Competitive Landscape

The Lyme Disease Diagnostic Market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are in the market are T2 Biosystems, Inc, Abbott, Bio-Rad Laboratories, Inc., Graphene Frontiers, Oxford Immunotec USA, Inc., Covance Inc. and ROCHE DIAGNOSTICS INTERNATIONAL LTD.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Lyme disease

      2. 4.2.2 Favourable government towards healthcare facilities

      3. 4.2.3 Emergence of new lyme diagnostic tests

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awarness regarding the disease

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By diagnostic technology

      1. 5.1.1 Serological test

        1. 5.1.1.1 ELISA

        2. 5.1.1.2 Western Blot

      2. 5.1.2 Lymphocytic transformation test

      3. 5.1.3 Urine Antigen Testing

      4. 5.1.4 Immunofluorescent staining

      5. 5.1.5 Nucleic acid test

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Clinical laboratories

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott

      2. 6.1.2 Bio-Rad Laboratories, Inc.

      3. 6.1.3 Covance Inc.

      4. 6.1.4 F. Hoffmann-La Roche AG

      5. 6.1.5 T2 Biosystems, Inc

      6. 6.1.6 Oxford Immunotec USA, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 5.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

T2 Biosystems, Inc, Bio-Rad Laboratories, Oxford Immunotec USA, Inc, ROCHE DIAGNOSTICS INTERNATIONAL LTD, Abbott are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!